CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). In previously-untreated patients, the objective response rate (ORR) (confirmed and unconfirmed) with pembrolizumab as a single-agent (monotherapy) was 47 percent by investigator-assessed, immune-related response criteria (irRC) (n=21/45: 95% CI, 32-62) and 26 percent by centrally evaluated RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) (n=11/42: 95% CI, 14-42). In evaluable patients who had measurable disease with one post baseline scan, 80 percent demonstrated tumor shrinkage as measured by centrally evaluated RECIST criteria (n=28/35). The median duration of response has not been reached, with some patients continuing on treatment with pembrolizumab as monotherapy for at least one year.
Help employers find you! Check out all the jobs and post your resume.
